

## ANNEXURE A


### Format of Initial Disclosure to be made by an entity identified as a Large Corporate

Sr. No.	Particulars	Details
1.	Name of the Company	Bliss GVS Pharma Limited
2.	CIN	L24230MH1984PLC034771
3.	Outstanding borrowing of company as on 31st March/ <del>31st December</del> , as applicable (in Rs. Lakhs)	3504.38
4.	Highest Credit Rating during the previous financial year alongwith name of the Credit Rating Agency	N.A.
5.	Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the framework	N.A.

We confirm that we are not a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018.



**Aditi Bhatt**  
Company Secretary  
Contact Details-022-42160000



**Vipul B. Thakkar**  
Chief Financial Officer  
Contact Details-022-42160000

Date: 30/04/2019

# - In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.